Wasatch BioLabs’ proprietary cell-free Whole Genome Methylation Sequencing (cfWGMS), powered by NESSI-Seq, sets a new standard in liquid biopsy analysis. Our technology preserves cell-free DNA (cfDNA) in its native form, enabling comprehensive shallow whole genome sequencing and methylation analysis in a single run, without the need for harsh chemical treatments or amplification. By leveraging our proprietary NESSI-Seq library preparation protocol, we deliver unmatched sensitivity and specificity, empowering researchers to uncover detailed genetic and epigenetic insights from even the most fragmented cfDNA samples:
The NESSI-Seq protocol is a proprietary library preparation protocol and third generation, native strand technology, capable of directly detecting native methylation and hydroxymethylation modifications. Direct, native detection bypasses the need for bisulfite conversion and PCR amplification, eliminating their associated biases and DNA damage.
WBL’s NESSI-Seq technology simplifies library prep and streamlines the acquisition of accurate DNA sequence and methylation data at single-molecule resolution.
The protocol is optimized to account for highly fragmented, nicked, and low concentration cfDNA (as low as 5ng / sample.)
Tissue-specific methylation patterns quantitatively identify cfDNA with WBL's cfWGMS: From an average of less than 100 reads per cfDNA dilution, the output revealed a correlation of R2 = 0.997 between predicted and true values.
Comparison between Tissue and blood plasma. cfDNA from Tissue 1 and blood plasma were bioinformatically mixed at various concentrations, and estimates for the proportion of Tissue 1-derived cfDNA in these mixed samples were calculated.
Differing amounts of female and male cfDNA were mixed (Figure 4). By analyzing the read depths of the X and Y chromosomes, relative copy numbers were captured to validate the efficacy of wgNESSIseq for CNV detection. wgNESSI-Seq quantitatively distinguished between copy numbers less than 25% apart.
Figure 4. Copy Number Variations can be detected with wgNESSI-Seq: Varying amounts of female and male cfDNA were mixed and sequenced via wgNESSI-Seq. NESSI-Seq accurately differentiated samples with copy number differences of less than 25%.
Maximize your sequencing output with WBL’s leading technology, streamlined bioinformatics pipelines, and expert guidance. WBL’s team of researchers are pioneers in Oxford Nanopore Technologies sequencing with decades of experience in genomics and bioinformatics research.
NGS 3.0 data with fully streamlined bioinformatics pipelines.
Results within 14-21 days of your sample’s arrival at the lab.
Teams of dedicated researchers and project managers to support your research and development.
Direct access to an online portal for sample information and batch status at each step of the sequencing process.
